Open-label, multicenter, phase II study of RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma - Sheng, X; Yan, X; Wang, L (Clin Cancer Res, 2021)